UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

Clinical cancer research, 2021-05, Vol.27 (10), p.2928-2937

2021

Volltextzugriff (PDF)

IRAK-4: A Novel Member of the IRAK Family with the Properties of an IRAK-Kinase

Proceedings of the National Academy of Sciences - PNAS, 2002-04, Vol.99 (8), p.5567-5572

2002

Volltextzugriff (PDF)

Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors

Bioorganic & medicinal chemistry letters, 2012-10, Vol.22 (19), p.6212-6217

2012

Volltextzugriff (PDF)

Sphingosine kinase activity is not required for tumor cell viability

PloS one, 2013-07, Vol.8 (7), p.e68328

2013

Volltextzugriff (PDF)

Sequential Autophosphorylation Steps in the Interleukin-1 Receptor-associated Kinase-1 Regulate its Availability as an Adapter in Interleukin-1 Signaling

The Journal of biological chemistry, 2004-02, Vol.279 (7), p.5227-5236

2004

Volltextzugriff (PDF)

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4

Bioorganic & medicinal chemistry letters, 2006-06, Vol.16 (11), p.2842-2845

2006

Volltextzugriff (PDF)

Metastatic Properties and Genomic Amplification of the Tyrosine Kinase Gene ACK1

Proceedings of the National Academy of Sciences - PNAS, 2005-11, Vol.102 (44), p.15901-15906

2005

Volltextzugriff (PDF)

Recruitment of IRAK to the Interleukin 1 Receptor Complex Requires Interleukin 1 Receptor Accessory Protein

Proceedings of the National Academy of Sciences - PNAS, 1997-11, Vol.94 (24), p.12829-12832

1997

Volltextzugriff (PDF)

Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.155-155

2020

Volltextzugriff (PDF)

The Growth Factor Midkine Antagonizes VEGF Signaling In Vitro and In Vivo

Neoplasia (New York, N.Y.), 2008-04, Vol.10 (4), p.340,IN3-346,IN3

2008

Volltextzugriff (PDF)

Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA–Cap Interaction

Journal of medicinal chemistry, 2012-04, Vol.55 (8), p.3837-3851

2012

Volltextzugriff (PDF)

Abstract 3364: Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3364-3364

2020

Volltextzugriff (PDF)

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.301-301

2019

Volltextzugriff (PDF)

Abstract LB-197: Bispecific T-cell engagers: evaluation of circulating tumor-associated antigen levels and pharmacokinetics

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-197-LB-197

2016

Volltextzugriff (PDF)

Structure guided design of a series of sphingosine kinase (SphK) inhibitors

Bioorganic & medicinal chemistry letters, 2013-08, Vol.23 (16), p.4608-4616

2013

Volltextzugriff (PDF)

Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper

Structure (London), 2006-12, Vol.14 (12), p.1835-1844

2006

Volltextzugriff (PDF)

Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4

Nature (London), 2002-04, Vol.416 (6882), p.750-756

2002

Volltextzugriff (PDF)

MyD88: an adapter that recruits IRAK to the IL-1 receptor complex

Immunity (Cambridge, Mass.), 1997-12, Vol.7 (6), p.837-847

1997

Volltextzugriff (PDF)

Abstract 2968: A novel bispecific CD3CDH19 antibody construct (CDH19 BiTE) directs potent killing of melanoma cells in vitro and in vivo and is enhanced by blockade of PD-L1

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2968-2968

2016

Volltextzugriff (PDF)

Abstract 2968: A novel bispecific CD3/CDH19 antibody construct (CDH19 BiTE) directs potent killing of melanoma cells in vitro and in vivo and is enhanced by blockade of PD-L1

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2968-2968

2016

Volltextzugriff (PDF)

Pillars article: MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997. 7: 837-847

The Journal of immunology (1950), 2013-01, Vol.190 (1), p.5-15

2013

Volltextzugriff (PDF)

Abstract LB-39: Sphingosine kinase activity is not required for tumor cell viability

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.LB-39-LB-39

2013

Volltextzugriff (PDF)

The SOC Estimation of LCO Battery Based on BP Neural Network

Energy, Transportation and Global Warming, p.543-552

Volltextzugriff (PDF)

An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1

Analytical biochemistry, 2007-08, Vol.367 (2), p.179-189

2007

Volltextzugriff (PDF)

Identification and optimization of N super(3),N super(6)-diaryl-1H- pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors

Bioorganic & medicinal chemistry, 2008-12, Vol.18 (24), p.6352-6356

2008

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(81)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

IRAK-4: A Novel Member of the IRAK Family with the Properties of an IRAK-Kinase

Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors

Sphingosine kinase activity is not required for tumor cell viability

Sequential Autophosphorylation Steps in the Interleukin-1 Receptor-associated Kinase-1 Regulate its Availability as an Adapter in Interleukin-1 Signaling

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4

Metastatic Properties and Genomic Amplification of the Tyrosine Kinase Gene ACK1

Recruitment of IRAK to the Interleukin 1 Receptor Complex Requires Interleukin 1 Receptor Accessory Protein

Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa)

The Growth Factor Midkine Antagonizes VEGF Signaling In Vitro and In Vivo

Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA–Cap Interaction

Abstract 3364: Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC)

Abstract LB-197: Bispecific T-cell engagers: evaluation of circulating tumor-associated antigen levels and pharmacokinetics

Structure guided design of a series of sphingosine kinase (SphK) inhibitors

Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper

Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4

MyD88: an adapter that recruits IRAK to the IL-1 receptor complex

Abstract 2968: A novel bispecific CD3CDH19 antibody construct (CDH19 BiTE) directs potent killing of melanoma cells in vitro and in vivo and is enhanced by blockade of PD-L1

Abstract 2968: A novel bispecific CD3/CDH19 antibody construct (CDH19 BiTE) directs potent killing of melanoma cells in vitro and in vivo and is enhanced by blockade of PD-L1

Pillars article: MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997. 7: 837-847

Abstract LB-39: Sphingosine kinase activity is not required for tumor cell viability

The SOC Estimation of LCO Battery Based on BP Neural Network

An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1

Identification and optimization of N super(3),N super(6)-diaryl-1H- pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors

Suchergebnisse filtern